Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma

Holly J. Meany, Vinod K. Gidvani, Caterina P. Minniti

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background. Positron emission tomography (PET) differentiates normal from abnormal cells based on metabolic activity. Numerous studies report that PET scan offers increased sensitivity, specificity and predictive values as compared to computed tomography (CT) in adult lymphoma patients. Procedure. Twenty-three consecutive pediatric Hodgkin lymphoma (HL) patients were evaluated with PET scan either at diagnosis or during treatment, then at therapy completion and in follow-up. Results. Twenty two of the 23 patients had a negative PET scan at the end of therapy; however, ten later developed a positive scan for a total of 11 (47.8%) patients with a positive post treatment PET scan. Six tissue biopsies were performed in five patients; four specimens were negative for disease and two confirmed HL relapse. Six patients were monitored clinically and remained asymptomatic; four had resolution of abnormalities on repeat PET while two had persistently positive, but stable PET scan findings and continue to be in remission at 11 and 40 months following treatment. Twelve (52.2%) patients of the original cohort have had consistently negative PET scans and have not relapsed. Conclusions. PET is a sensitive (100%), but not a specific (57.1%) method for evaluating post-treatment pediatric HL patients with a strong negative predictive value (NPV; 100%), but poor positive predictive value (PPV; 18.2%). We do not recommend treatment decisions be based solely on PET scan results.

Original languageEnglish (US)
Pages (from-to)399-402
Number of pages4
JournalPediatric Blood and Cancer
Volume48
Issue number4
DOIs
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Hodgkin Disease
Positron-Emission Tomography
Pediatrics
Recurrence
Therapeutics
Lymphoma
Tomography
Biopsy
Sensitivity and Specificity

Keywords

  • Hodgkin lymphoma
  • Pediatric
  • Positron emission tomography

ASJC Scopus subject areas

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma. / Meany, Holly J.; Gidvani, Vinod K.; Minniti, Caterina P.

In: Pediatric Blood and Cancer, Vol. 48, No. 4, 04.2007, p. 399-402.

Research output: Contribution to journalArticle

@article{54db965687a34e1eb4a6eba5328335f3,
title = "Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma",
abstract = "Background. Positron emission tomography (PET) differentiates normal from abnormal cells based on metabolic activity. Numerous studies report that PET scan offers increased sensitivity, specificity and predictive values as compared to computed tomography (CT) in adult lymphoma patients. Procedure. Twenty-three consecutive pediatric Hodgkin lymphoma (HL) patients were evaluated with PET scan either at diagnosis or during treatment, then at therapy completion and in follow-up. Results. Twenty two of the 23 patients had a negative PET scan at the end of therapy; however, ten later developed a positive scan for a total of 11 (47.8{\%}) patients with a positive post treatment PET scan. Six tissue biopsies were performed in five patients; four specimens were negative for disease and two confirmed HL relapse. Six patients were monitored clinically and remained asymptomatic; four had resolution of abnormalities on repeat PET while two had persistently positive, but stable PET scan findings and continue to be in remission at 11 and 40 months following treatment. Twelve (52.2{\%}) patients of the original cohort have had consistently negative PET scans and have not relapsed. Conclusions. PET is a sensitive (100{\%}), but not a specific (57.1{\%}) method for evaluating post-treatment pediatric HL patients with a strong negative predictive value (NPV; 100{\%}), but poor positive predictive value (PPV; 18.2{\%}). We do not recommend treatment decisions be based solely on PET scan results.",
keywords = "Hodgkin lymphoma, Pediatric, Positron emission tomography",
author = "Meany, {Holly J.} and Gidvani, {Vinod K.} and Minniti, {Caterina P.}",
year = "2007",
month = "4",
doi = "10.1002/pbc.20797",
language = "English (US)",
volume = "48",
pages = "399--402",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Utility of PET scans to predict disease relapse in pediatric patients with Hodgkin lymphoma

AU - Meany, Holly J.

AU - Gidvani, Vinod K.

AU - Minniti, Caterina P.

PY - 2007/4

Y1 - 2007/4

N2 - Background. Positron emission tomography (PET) differentiates normal from abnormal cells based on metabolic activity. Numerous studies report that PET scan offers increased sensitivity, specificity and predictive values as compared to computed tomography (CT) in adult lymphoma patients. Procedure. Twenty-three consecutive pediatric Hodgkin lymphoma (HL) patients were evaluated with PET scan either at diagnosis or during treatment, then at therapy completion and in follow-up. Results. Twenty two of the 23 patients had a negative PET scan at the end of therapy; however, ten later developed a positive scan for a total of 11 (47.8%) patients with a positive post treatment PET scan. Six tissue biopsies were performed in five patients; four specimens were negative for disease and two confirmed HL relapse. Six patients were monitored clinically and remained asymptomatic; four had resolution of abnormalities on repeat PET while two had persistently positive, but stable PET scan findings and continue to be in remission at 11 and 40 months following treatment. Twelve (52.2%) patients of the original cohort have had consistently negative PET scans and have not relapsed. Conclusions. PET is a sensitive (100%), but not a specific (57.1%) method for evaluating post-treatment pediatric HL patients with a strong negative predictive value (NPV; 100%), but poor positive predictive value (PPV; 18.2%). We do not recommend treatment decisions be based solely on PET scan results.

AB - Background. Positron emission tomography (PET) differentiates normal from abnormal cells based on metabolic activity. Numerous studies report that PET scan offers increased sensitivity, specificity and predictive values as compared to computed tomography (CT) in adult lymphoma patients. Procedure. Twenty-three consecutive pediatric Hodgkin lymphoma (HL) patients were evaluated with PET scan either at diagnosis or during treatment, then at therapy completion and in follow-up. Results. Twenty two of the 23 patients had a negative PET scan at the end of therapy; however, ten later developed a positive scan for a total of 11 (47.8%) patients with a positive post treatment PET scan. Six tissue biopsies were performed in five patients; four specimens were negative for disease and two confirmed HL relapse. Six patients were monitored clinically and remained asymptomatic; four had resolution of abnormalities on repeat PET while two had persistently positive, but stable PET scan findings and continue to be in remission at 11 and 40 months following treatment. Twelve (52.2%) patients of the original cohort have had consistently negative PET scans and have not relapsed. Conclusions. PET is a sensitive (100%), but not a specific (57.1%) method for evaluating post-treatment pediatric HL patients with a strong negative predictive value (NPV; 100%), but poor positive predictive value (PPV; 18.2%). We do not recommend treatment decisions be based solely on PET scan results.

KW - Hodgkin lymphoma

KW - Pediatric

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=33847378045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847378045&partnerID=8YFLogxK

U2 - 10.1002/pbc.20797

DO - 10.1002/pbc.20797

M3 - Article

C2 - 16514616

AN - SCOPUS:33847378045

VL - 48

SP - 399

EP - 402

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -